Compare CVM & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVM | MDCX |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4M | 26.2M |
| IPO Year | 1996 | N/A |
| Metric | CVM | MDCX |
|---|---|---|
| Price | $3.66 | $0.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 39.0K | ★ 8.2M |
| Earning Date | 02-18-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $264,033.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.45 | N/A |
| 52 Week Low | $0.18 | $0.37 |
| 52 Week High | $13.48 | $8.90 |
| Indicator | CVM | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | 31.88 |
| Support Level | $3.34 | $0.37 |
| Resistance Level | $6.82 | $1.43 |
| Average True Range (ATR) | 0.32 | 0.15 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 49.40 | 9.52 |
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.